This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Quetiapine-Induced Hypersalivation

Shannon Allen, BS; Zachary Hoffer, PhD; and Maju Mathews, MD, FRCPsych

Published: June 15, 2007

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Quetiapine fumarate is a dibenzothiazepinederivativeantipsychotic with combined antagonism atdopamine (D1, D2) and serotonin type 1 and type 2 (5-HT1A,5-HT2A, 5-HT2C) receptors. Additionally, quetiapine antagonizesα1– and α2-adrenergic andhistamine H1 receptors.Protean binding at the above receptors explains thecommon side effects, which include hypersomnolence,hypotension, headache, weight gain, and gastrointestinaldisturbance.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 9

Quick Links: Psychotic Disorders , Schizophrenia and Schizoaffective Disorders

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...